Target Therapies in Lung Cancer

被引：12

作者：

Bearz, A. ^{[1
]}

Berretta, M. ^{[1
]}

Lleshi, A. ^{[1
]}

Tirelli, U. ^{[1
]}

机构：

[1] CRO IRCCS, Dept Med Oncol, Natl Canc Inst, I-33081 Aviano, Italy

来源：

JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY | 2011年

关键词：

GROWTH-FACTOR RECEPTOR; PREVIOUSLY TREATED PATIENTS; PHASE-II TRIAL; OPEN-LABEL; GEFITINIB; PLUS; MUTATIONS; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

D O I：

10.1155/2011/921231

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has reached a plateau regarding overall survival, and target therapies could offer the possibility to improve patients' outcome beyond cytotoxic activity. The goal for target therapies is to identify agents that target tumor-specific molecules, thus sparing normal tissues; those molecules are called biomarkers, and their identification is recommended because it has a predictive value, for example, provides information on outcome with regard to a specific treatment. The increased specificity should lead to decreased toxicity and better activity. Herein we provide an update of the main target therapies in development or already available for the treatment of nonsmall cell lung cancer.

引用

页数：5